Silo Pharma, Inc.
SILO evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $3.7M
- Lead Asset:
- SP-26 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for SILO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SILO
Silo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical and cryptocurrency company focused on developing novel therapeutics for underserved CNS conditions, including PTSD, anxiety, fibromyalgia, and Alzheimer's disease, with lead candidate SPC-15 targeting stress-induced psychiatric disorders.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.7M
Cash Runway
—
Lead Asset
SP-26 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Silo Pharma, Inc..
Silo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical and cryptocurrency company focused on developing novel therapeutics for underserved CNS conditions, including PTSD, anxiety, fibromyalgia, and Alzheimer's disease, with lead candidate SPC-15 targeting stress-induced psychiatric disorders.
- Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency company [sec · filed 2026-07-24].
- Lead program SPC-15 is an intranasal serotonin 4 (5-HT4) receptor agonist for PTSD and stress-induced anxiety disorders [sec_mda · as of 2026-08-13].
- The company holds an exclusive license agreement with Columbia University for ketamine combination therapies for Alzheimer's and depression [sec · filed 2026-07-24].
- Cash & equivalents were $3.3M as of 2026-06-30, with net income of -$0.8M and shareholders' equity of $4.9M [sec].
- A European Patent Office (EPO) patent was granted in August 2026 covering the preventative approach of SPC-15 [news · published 2026-08-10].
What works
- Lead candidate SPC-15 has received expanded patent protection in the U.S., Australia, Japan, and Europe, strengthening global IP for its novel preventative approach [news · published 2025-10-23][news · published 2026-08-10].
- The company has established a scientific advisory board and collaborations with world-renowned institutions, including a sponsored research agreement with Columbia University [sec · filed 2026-07-24].
- SP-26 is being developed under the FDA's 505(b)(2) regulatory pathway, which may allow reliance on existing public data to reduce development time and cost [sec_mda · as of 2026-05-14].
What to weigh
- The company is a developmental-stage entity with no approved products and reported a net loss of -$0.8M for the period ending 2026-06-30 [sec].
- Cash reserves are limited at $3.3M as of 2026-06-30, which may constrain the ability to fund multiple preclinical and clinical programs simultaneously [sec].
- All product candidates (SPC-15, SP-26, SPC-14, SPU-16) are in preclinical or early development stages, with no disclosed clinical trial data [sec_mda · as of 2026-08-13].
- The company's dual focus on biopharmaceuticals and cryptocurrency introduces additional business model complexity and risk [sec · filed 2026-07-24].
From the filings
Quoted directly from source documents.
Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency company.
“We are a diversified developmental-stage biopharmaceutical and cryptocurrency company.”
SEC filings · July 24, 2026
SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist administered intranasally for PTSD and anxiety.
“SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. This innovative treatment is administered via an intranasal formulation”
SEC MD&A · August 13, 2026
The company has an exclusive license agreement with Columbia University for ketamine combination therapies.
“we have also entered into an exclusive license agreement with Columbia under which we have rights to certain patents and inventions relating to the treatment of Alzheimer's disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.”
SEC filings · July 24, 2026
EPO granted a patent for SPC-15's preventative approach in August 2026.
“Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15”
News · August 10, 2026
Risks & what to watch (3)›
Key risks
- No approved products — All programs are preclinical; no revenue from product sales [sec_mda · as of 2026-08-13].
- Limited cash runway — Cash & equivalents $3.3M as of 2026-06-30; net loss -$0.8M [sec].
- Business model complexity — Dual focus on biopharma and cryptocurrency adds execution risk [sec · filed 2026-07-24].
What to watch
- Progress of SPC-15 into clinical trials, given recent patent expansions and IND-enabling studies [news · published 2025-10-23].
- Financial sustainability: cash position of $3.3M as of 2026-06-30 and ongoing net losses [sec].
- Development of SP-26 under the 505(b)(2) pathway and any partnership or licensing updates [sec_mda · as of 2026-05-14].
- Outcomes of the Columbia University collaboration for ketamine-based Alzheimer's and depression treatments [sec · filed 2026-07-24].
Sources: News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Silo Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Silo Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.22 · 0% dilution
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$380K
| Holder | Shares | Value |
|---|---|---|
| advisorshares investments llc | 663,965 | $239K |
| geode capital management, llc | 180,031 | $65K |
| susquehanna international group, llp | 62,795 | $23K |
| jane street group, llc | 44,763 | $16K |
| citadel advisors llc | 21,448 | $8K |
| xtx topco ltd | 17,083 | $6K |
| two sigma securities, llc | 14,503 | $5K |
| vanguard fiduciary trust co | 13,100 | $5K |
| lpl financial llc | 12,534 | $5K |
| state street corp | 12,500 | $4K |
Showing top 10 of 15 institutional holders of Silo Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 3.3%
- Days to cover
- 0.1
- Shares short
- 522,541
- Daily short volume (Oct 9, 2026)
- 72.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SILO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Silo Pharma, Inc.?
Silo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical and cryptocurrency company focused on developing novel therapeutics for underserved CNS conditions, including PTSD, anxiety, fibromyalgia, and Alzheimer's disease, with lead candidate SPC-15 targeting stress-induced psychiatric disorders.
What is Silo Pharma, Inc.'s lead drug candidate?
Silo Pharma, Inc.'s most advanced tracked candidate is SP-26 (Preclinical) for Fibromyalgia and chronic pain.
Who is the CEO of Silo Pharma, Inc.?
Mr. Eric Weisblum is the chief executive officer of Silo Pharma, Inc. (SILO).
Where is Silo Pharma, Inc. headquartered?
Silo Pharma, Inc. (SILO) is headquartered in Sarasota, FL, United States.
What therapeutic areas does Silo Pharma, Inc. focus on?
Silo Pharma, Inc. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.